IRVINGTON, N.Y.--(BUSINESS WIRE)--MELA Sciences, Inc. (NASDAQ:MELA), developer of the MelaFind® system, an FDA approved optical diagnostic device that assists dermatologists in the diagnosis of melanoma, today announced that it has concluded an agreement with the sixth and final investigative site participating in the Company’s post-approval study (PAS) of the MelaFind® system for the diagnosis of melanoma. More than 100 patients have been enrolled in the study to date.
Help employers find you! Check out all the jobs and post your resume.
